ACTUATE THERAPEUTICS, INC. (ACTU) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.00

From 52W high−88.13%

Volume108989.00

Market cap$23.06M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$1.00

From 52W high

−88.13%

Volume

108989.00

Market cap

$23.06M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.9x

P/E (TTM)

—

RSI (14)

39.6

MomentumView details →

1D Return

−3.52%

YTD Return

−83.33%

SummaryUpdated Jun 1, 2026

Actuate Therapeutics Inc (NASDAQ:ACTU) is a clinical-stage biopharmaceutical company founded in 2015 and based in Fort Worth, Texas. Originally incorporated as Apotheca Therapeutics, the company changed its name to Actuate Therapeutics in October 2015. The company went public in August 2024 and focuses on developing novel cancer therapies, with its lead product candidate being a glycogen synthase kinase-3 inhibitor for treating various forms of cancer including pancreatic, colorectal, and rare cancers.

Ask drillr about ACTUATE THERAPEUTICS, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

23.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−2067.81%

ROA (TTM)

−393.39%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+49.72%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+67.48%

EBITDA YoY

+16.58%

MomentumView details →

1D Return

−3.52%

YTD Return

−83.33%

1Y Return

−84.64%

RSI (14)

39.6

vs 50D SMA

−18.46%

vs 200D SMA

−66.74%

Capital & dividendView details →

Debt/Equity

0.41x

Current Ratio

1.25x

Quick Ratio

1.25x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.20

EPS Surprise

4.76%

Beats (12Q)

3/12

Next Q EPS Est

−$0.17

Avg Surprise (4Q)

8.21%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−20.45M

Op. CF (TTM)

−19.84M

Next earningsNov 12, 2026 →

Latest newsMore news →

No recent news for ACTU.

Similar companies

Estrella Immunopharma, Inc.ESLA Cocrystal Pharma, Inc.COCP Klotho Neurosciences, Inc.KLTO Cellectar Biosciences, Inc.CLRB Radiopharm Theranostics LimitedRADX GridAI Technologies Corp.GRDX Find similar companies →

Latest newsMore news →

No recent news for ACTU.